Skip to main content

Table 1 Anti-proliferative activity of TAE226 against cancer cell lines

From: Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models

Cell origin Cell line name GI50 (μM) n
Breast MCF-7 1.2 ± 0.22 7
MCF-7/ADR-RES 1.1 ± 0.23 4
MDA-MB-231 0.56 ± 0.22 3
MDA-MB-435 1.6 ± 0.044 3
MDA-MB-453 1.5 ± 0.32 3
4T1 0.16 ± 0.022 5
MTF7 1.4 ± 0.26 3
Prostate DU145 0.23 (0.20, 0.25) 2
PC-3/M 0.83 ± 0.29 4
Lung NCI-H23 0.29 (0.24, 0.35) 2
NCI-H460 0.40 ± 0.028 4
LLC 0.13 ± 0.0077 4
Colon COLO205 0.21 (0.11, 0.30) 2
HCT-15 0.71 ± 0.1 5
HCT-116 0.42 ± 0.056 3
SW620 0.51 ± 0.024 3
WiDr 0.14 ± 0.030 5
Stomach KATOIII 0.54 ± 0.064 3
Pancreas BxPC-3 0.53 ± 0.11 3
MIA PaCa-2 0.26 ± 0.062 4
PANC-1 3.6 ± 0.93 3
SUIT-2 0.18 ± 0.029 3
Glioma A172 1.6 (2.2, 1.1) 2
DBTRG-05MG 0.47 ± 0.054 3
LN-18 0.96 ± 0.12 3
LN-229 0.56 ± 0.043 3
T98G 0.42 (0.21, 0.63) 2
U-87 MG 1.0 (1.1, 0.97) 2
U-118 MG 1.3 (0.69, 1.8) 2
U-373 MG 1.4 (0.72, 2.0) 2
Melanoma A375M 0.29 (0.15, 0.43) 2
C32 1.8 ± 0.31 3
C8161 0.90 (0.68, 1.1) 2
SK-MEL-23 0.17 ± 0.0090 3
SK-MEL-93 0.25 ± 0.050 4
WM1158 0.33 ± 0.099 3
Myeloma RPMI8226 0.33 ± 0.060 3
  1. TAE226 concentrations causing 50% inhibition of net cell growth (GI50) are given. Results are expressed as mean ± SEM (except experiments with n = 2 where 2 individual values are included). Cell growth was assessed by sulforhodamine B staining for adhesive cell lines and by AlamarBlue for suspension cell lines. GI50 values were calculated after 48 h treatment with TAE226